Loading clinical trials...
Loading clinical trials...
A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study)
Conditions
Interventions
Sunitinib Malate (SU011248)
Locations
11
China
Pfizer Investigational Site
Guangzhou, Guangdong, China
Pfizer Investigational Site
Wuhan, Hubei, China
Pfizer Investigational Site
Nanjing, Jiangsu, China
Pfizer Investigational Site
Beijing, China
Pfizer Investigational Site
Beijing, China
Pfizer Investigational Site
Beijing, China
Start Date
July 1, 2008
Primary Completion Date
August 1, 2011
Completion Date
August 1, 2011
Last Updated
January 18, 2013
NCT07227415
NCT05127824
NCT05865730
NCT05239728
NCT04028245
NCT04338269
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions